6533b7d1fe1ef96bd125d7c7

RESEARCH PRODUCT

Type 2 diabetes mellitus and osteoarthritis

André ScheenRené RizzoliRoland RothLucio C. RovatiMarc C. HochbergMila VlaskovskaElaine M. DennisonNicola VeroneseDaniel UebelhartEmmanuel MaheuJean-françois KauxGabriel Herrero-beaumontOlivier BruyèreJaime BrancoRoland ChapurlatCyrus CooperNasser M. Al-daghriJean-yves Reginster

subject

medicine.medical_specialtyEvidence-based practicetype 2 diabetes mellituendocrine system diseasesMedicinaOsteoarthritisOverweightPathophysiologyArticle03 medical and health sciences0302 clinical medicineInsulin resistanceRheumatologyInternal medicineOsteoarthritisType 2 diabetes mellitusMedicineHumans030212 general & internal medicineObesityRisk factor030203 arthritis & rheumatologyddc:616[SDV.MHEP.EM] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism[SDV.MHEP.RSOA] Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal systembusiness.industryType 2 Diabetes Mellitusnutritional and metabolic diseases[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismmedicine.diseaseObesity3. Good healthInstitutional repositoryAnesthesiology and Pain MedicineDiabetes Mellitus Type 2[SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal systemDisease Progressionosteoarthritimedicine.symptomInsulin ResistanceSafetybusiness

description

Objectives: Type 2 diabetes mellitus (T2DM) and osteoarthritis (OA) are common diseases that frequently co-exist, along with overweight/obesity. While the mechanical impact of excess body weight on joints may explain lower limb OA, we sought to explore whether T2DM is linked to OA outside of excess weight and whether T2DM may play a role in OA pathophysiology. The consequence of T2DM on OA outcomes is a question of research interest. Methods: We conducted a critical review of the literature to explore the association between T2DM and OA, whether any association is site-specific for OA, and whether the presence of T2DM impacts on OA outcomes. We also reviewed the literature to assess the safety of anti-OA treatments in patients with T2DM. Results: T2DM has a pathogenic effect on OA through 2 major pathways involving oxidative stress and low-grade chronic inflammation resulting from chronic hyperglycemia and insulin resistance. T2DM is a risk factor for OA progression and has a negative impact on arthroplasty outcomes. Evidence is mounting for safety concerns with some of the most frequently prescribed anti-OA medications, including paracetamol, non-steroidal anti-inflammatory drugs, and corticosteroid injections, while other anti-OA medications may be safely prescribed in OA patients with T2DM, such as glucosamine and intra-articular hyaluronic acid. Conclusions: Future research is needed to better understand whether diabetes control and prevention can modulate OA occurrence and progression. The selection of therapy to treat OA symptoms in patients with T2DM may require careful consideration of the evidence based to avoid untoward safety issues.

10.1016/j.semarthrit.2019.01.005https://doi.org/10.1016/j.semarthrit.2019.01.005